Imetelstat for Lower-Risk MDS: Data From the IMerge Trial
Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.
Source: onclive.com
Mds Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mds Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mds Management Today - Breaking & Trending Today
Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial
Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.
Source: onclive.com
ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS
Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.
Source: onclive.com
Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation
Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.
Source: onclive.com
Treatment Approaches for Lower-Risk MDS With RAS Mutations
The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.
Source: onclive.com